Skip to main content
    C

    Corvus Pharmaceuticals Inc (CRVS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $10.60
    -0.04 (-0.38%)

    Market Cap: $897.52M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Corvus Pharmaceuticals Inc (CRVS) Financials: Revenue, Profit and Cash Flow

    Updated Nov 5, 2026. Financial statements from company filings, amounts in US dollars.

    Corvus Pharmaceuticals reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$15.28M, operating cash flow was -$32.80M and free cash flow was -$32.97M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$20.34M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $42.97M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0-100.0%N/AN/AN/A
    Dec 2021$235.00KN/A100.0%-16438.3%-18400.4%
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0N/AN/AN/AN/A
    Dec 2018$0N/AN/AN/AN/A
    Dec 2017$0N/AN/AN/AN/A
    Dec 2016$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$0$0$0$0$235.00K$0$0$0$0$0
    Gross profit$0$0$0$0$235.00K$0$0$0$0$0
    Research and development$33.72M$19.39M$16.53M$24.47M$29.11M$31.83M$37.98M$38.59M$46.30M$29.36M
    Operating income-$42.97M-$27.55M-$23.41M-$32.56M-$38.63M-$43.76M-$48.85M-$49.22M-$56.52M-$36.98M
    Net income-$15.28M-$62.29M-$27.03M-$41.31M-$43.24M-$6.00M-$46.67M-$46.94M-$55.66M-$36.38M
    EBITDA-$17.07MN/AN/A-$32.37M-$38.17M-$43.36M-$48.76M-$48.38M-$55.88M-$35.73M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$0$0$0$0$0$0$88.00K$0$0$0$246.00K
    Gross profit$0$0$0-$26.00K$0$0$0$44.00K$0$0$0$218.00K
    Operating income-$21.36M-$19.30M-$14.88M-$12.22M-$10.57M-$10.26M-$9.92M-$8.11M-$7.25M-$5.93M-$6.25M-$5.65M
    Net income-$20.34M-$17.96M-$13.69M-$12.32M-$10.16M-$8.00M$15.19M-$12.11M-$40.22M-$4.26M-$5.70M-$6.65M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $403.00K by $4.17M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$71.12M$68.91M$45.55M$68.24M$109.45M$85.53M$83.65M$118.23M$94.78M$140.15M
    Current assets$58.21M$54.41M$27.96M$43.66M$71.31M$45.34M$79.34M$115.59M$91.23M$136.03M
    Cash and equivalents$4.58M$8.74M$12.62M$13.16M$63.46M$16.45M$5.15M$39.20M$45.11M$5.05M
    Total liabilities$9.91M$36.34M$6.87M$12.13M$12.29M$13.38M$12.54M$7.90M$9.94M$7.35M
    Short-term debt$403.00K$185.00K$1.37M$1.23M$1.05M$1.08M$878.00KN/AN/AN/A
    Shareholder equity$61.20M$32.57M$38.68M$56.12M$97.16M$72.15M$71.11M$110.34M$84.83M$132.80M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$223.88M$239.27M$253.19M$71.12M$80.47M$89.46M$59.44M$68.91M$58.81M$64.56M$40.08M$45.55M
    Total liabilities$15.56M$13.95M$12.52M$9.91M$8.71M$9.23M$10.11M$36.34M$46.41M$13.34M$6.72M$6.87M
    Cash and equivalents$15.01M$18.91M$40.10M$4.58M$2.87M$14.69M$5.00M$8.74M$4.68M$14.84M$7.46M$12.62M
    Shareholder equity$208.32M$225.33M$240.68M$61.20M$71.77M$80.23M$49.33M$32.57M$12.41M$51.23M$33.36M$38.68M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$32.80M-$25.42M-$23.93M-$27.02M-$36.72M-$34.78M-$37.32M-$40.99M-$46.21M-$27.86M
    Capital expenditures$174.00K$0$34.00K$269.00K$5.00K$76.00K$25.00K$355.00K$266.00K$2.20M
    Free cash flow-$32.97M-$25.42M-$23.97M-$27.29M-$36.72M-$34.85M-$37.35M-$41.34M-$46.48M-$30.06M
    Investing cash flow-$7.80M-$27.48M$15.54M-$23.28M$21.56M$44.77M$3.25M-$30.19M$84.83M-$42.56M
    Financing cash flow$36.43M$49.03M$7.86M$0$62.16M$1.31M$24.00K$65.27M$1.44M$71.36M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$12.21M-$15.40M-$10.37M-$9.19M-$9.57M-$5.78M-$8.26M-$8.46M-$6.32M-$5.48M-$5.16M-$5.17M
    Capital expenditures$66.00K$582.00K$91.00K$25.00K$0$113.00K$36.00K$0$0$0$0$0
    Free cash flow-$12.28M-$15.98M-$10.46M-$9.22M-$9.57M-$5.89M-$8.30M-$8.46M-$6.32M-$5.48M-$5.16M-$5.17M
    Last 12 quarters

    Frequently Asked Questions About CRVS

    What is Corvus Pharmaceuticals' annual revenue?

    Corvus Pharmaceuticals reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Corvus Pharmaceuticals profitable?

    No. Corvus Pharmaceuticals reported net income of -$15.28M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does CRVS generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$32.80M minus capital expenditures of $174.00K produced free cash flow of -$32.97M.

    How much debt does Corvus Pharmaceuticals have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $403.00K and cash and equivalents of $4.58M.